The StemMedical platform is unique within mesenchymal stem cells (MSCs) production given its ability to produce potent MSCs in 10-20 billion batches and can address multiple application areas. StemMedical has set out to scale its cell treatments that dramatically improve a patient’s quality of life, and is already today working with patients, leading healthcare professionals, and academia to succeed.
Clinical studies have shown that MSCs hold the potential to treat various musculoskeletal, respiratory, cardiovascular, and gastrointestinal disorders such as osteoarthritis, asthma, ischemia-reperfusion injury, inflammatory bowel diseases, type 1 diabetes, and chronic wounds.
Osteoarthritis (OA) of the knee, with more than 300 million patients worldwide, has shown promising clinical results with the use of MSCs and the StemMedical platform is uniquely suited to deliver a differentiated product in OA. Following careful analyses, StemMedical has initiated the first clinical development program for treatment of knee OA, with a clinical proof of concept trial planned for 2024.